HeyJaredCardiology Trial’s Substack
A review of clinical trials in cardiovascular medicine that have had a major impact on the field. The trials are indexed according to major subject headings and presented in chronological order of publication date.
- Indexed issues, last 90 days
- 12
- Latest publication
- Sep 29, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 28, 2026
Latest issues
Review of the PFA-SHAM trial (opens the original)
Read excerpt
Circulation 2026;153:1984-1998Background: Catheter ablation for atrial fibrillation (AF) is one of the most commonly performed cardiovascular procedures, and randomized trials have shown that it outperforms antiarrhythmic drugs at preventing arrhythmia recurrence. A mortality benefit was seen in patients with systolic heart failure (see CASTLE -AF and CASTLE-HTx - these trials had limita
Review of the SHAM-PVI trial (opens the original)
Read excerpt
JAMA. 2024;332(14):1165-1173Background: Pulmonary vein isolation (PVI) for atrial fibrillation (AF) is a frequently performed procedure. At the time of writing this review, it’s estimated that over 100,000 AF ablation procedures are performed in the United States each year. Prior trials of AF ablation showed reduction in AF burden and improvement in symptoms and quality of life. However, these trials were unblinded making these endpoints subject to performance bias and/or placebo effect. The SHA
Summary and discussion of CABANA and EARLY-AF (opens the original)
Review of the CASTLE-HTx trial (opens the original)
Read excerpt
N Engl J Med. 2023;389(15):1380-1389.Background: Catheter ablation was tested in patients with atrial fibrillation (AF) and heart failure (HF). However, prior trials, notably in CASTLE-AF and RAFT-AF, didn’t include patients with advanced end-stage heart failure - those already being evaluated for heart transplantation or left ventricular assist device (LVAD) implan
Review of the RAFT-AF trial (opens the original)
Read excerpt
Circulation 2022;145:1693-1704 Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist. Patients with both conditions carry worse prognosis than patients with either condition alone. Pharmacologically based rhythm control has not been shown to be superior to rate control for AF in patients with HF, in trials such as AFFIRM and AF-CHF. Whether catheter abla
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.